These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21259038)

  • 1. Exacerbation history is associated with medication and appointment adherence in MS.
    Hancock LM; Bruce JM; Lynch SG
    J Behav Med; 2011 Oct; 34(5):330-8. PubMed ID: 21259038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis.
    Moccia M; Palladino R; Russo C; Massarelli M; Nardone A; Triassi M; Lugaresi A; Brescia Morra V
    Expert Opin Drug Deliv; 2015; 12(12):1829-35. PubMed ID: 26371561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probability discounting of treatment decisions in multiple sclerosis: associations with disease knowledge, neuropsychiatric status, and adherence.
    Bruce JM; Bruce AS; Lynch S; Thelen J; Lim SL; Smith J; Catley D; Reed DD; Jarmolowicz DP
    Psychopharmacology (Berl); 2018 Nov; 235(11):3303-3313. PubMed ID: 30244284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
    Lenz F; Harms L
    Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Injectable disease-modifying therapy for relapsing-remitting multiple sclerosis: a review of adherence data.
    Caon C; Saunders C; Smrtka J; Baxter N; Shoemaker J
    J Neurosci Nurs; 2010 Oct; 42(5 Suppl):S5-9. PubMed ID: 21049828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition.
    Bruce JM; Hancock LM; Arnett P; Lynch S
    J Behav Med; 2010 Jun; 33(3):219-27. PubMed ID: 20127401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis: MS treatment adherence--how to keep patients on medication?
    Bruce JM; Lynch SG
    Nat Rev Neurol; 2011 Jul; 7(8):421-2. PubMed ID: 21727939
    [No Abstract]   [Full Text] [Related]  

  • 8. A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.
    Zwibel H; Pardo G; Smith S; Denney D; Oleen-Burkey M
    J Neurol; 2011 Mar; 258(3):402-11. PubMed ID: 20922405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beliefs about medication as predictors of medication adherence in a prospective cohort study among persons with multiple sclerosis.
    Neter E; Glass-Marmor L; Wolkowitz A; Lavi I; Miller A
    BMC Neurol; 2021 Mar; 21(1):136. PubMed ID: 33761887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis.
    Fraser C; Hadjimichael O; Vollmer T
    J Neurosci Nurs; 2001 Oct; 33(5):231-9. PubMed ID: 11668881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis.
    Lafata JE; Cerghet M; Dobie E; Schultz L; Tunceli K; Reuther J; Elias S
    J Am Pharm Assoc (2003); 2008; 48(6):752-7. PubMed ID: 19019804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Who is not coming to clinic? A predictive model of excessive missed appointments in persons with multiple sclerosis.
    Gromisch ES; Turner AP; Leipertz SL; Beauvais J; Haselkorn JK
    Mult Scler Relat Disord; 2020 Feb; 38():101513. PubMed ID: 31756611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis.
    Hupperts R; Ghazi-Visser L; Martins Silva A; Arvanitis M; Kuusisto H; Marhardt K; Vlaikidis N;
    Clin Ther; 2014 Dec; 36(12):1946-1957. PubMed ID: 24811754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction: adherence to disease-modifying therapies--key to optimizing outcomes in relapsing multiple sclerosis.
    Caon C; Saunders C; Smrtka J; Davis K; Davis A; Kay JM; Baxter N
    J Neurosci Nurs; 2010 Oct; 42(5 Suppl):S1-4. PubMed ID: 21049827
    [No Abstract]   [Full Text] [Related]  

  • 15. Discontinuing Treatment Against Medical Advice: The Role of Perceived Autonomy Support From Providers in Relapsing-Remitting Multiple Sclerosis.
    Glusman M; Bruce A; Thelen J; Smith J; Lynch S; Catley D; Bennett KK; Bruce J
    Ann Behav Med; 2019 Mar; 53(3):283-289. PubMed ID: 29771271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to self-administering interferon-β1a using RebiSmart® device in Mexican patients with relapsing multiple sclerosis.
    Sauri-Suárez S; Quiñones-Aguilar S; Contreras-Marín A; Ramiro-Guerrero EO; Zúñiga-García D; Salinas-Vázquez L; Llamas-López L; León-Jiménez C; García-Martell A; González-Hernández I; Chiquete E; García S
    PLoS One; 2020; 15(4):e0230959. PubMed ID: 32310950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study.
    Zecca C; Disanto G; Mühl S; Gobbi C
    BMC Neurol; 2017 Sep; 17(1):171. PubMed ID: 28870152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effects of Negative Reinforcement on Increasing Patient Adherence to Appointments at King Abdullah University Hospital in Jordan.
    Alyahya M; Hijazi HH; Nusairat FT
    Inquiry; 2016; 53():. PubMed ID: 27444505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appointment length, psychiatrists' communication behaviors, and medication management appointment adherence.
    Cruz M; Roter DL; Cruz RF; Wieland M; Larson S; Cooper LA; Pincus HA
    Psychiatr Serv; 2013 Sep; 64(9):886-92. PubMed ID: 23771555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.